PresseBox
Press release BoxID: 172421 (PULSION Medical Systems SE)
  • PULSION Medical Systems SE
  • Hans-Riedl-Str. 21
  • 85622 Feldkirchen
  • http://www.pulsion.com/
  • Contact person
  • Christian Steiner
  • +49 (89) 459914-200

Frank Posnanski appointed as new CFO

PULSION’s Management Board trio complete again

(PresseBox) (München, ) The Supervisory Board of PULSION Medical Systems AG, a life science corporation specializing in medical diagnostic and therapy systems, listed on the Prime Standard of the Frankfurt Stock Exchange, has appointed Frank Posnanski, a business mathematician, as Chief Financial Officer with effect from June 1, 2008. Mr. Posnanski will join Bradley Gould (Chairman) and Matthias Bohn (COO) on the PULSION Management Board, taking over responsibility for the areas Finance, Investor Relations and Administration.

The 41 year-old Frank Posnanski succeeds Stefan Land who left the company last year. Mr. Posnanski was previously divisional head of controlling with Kabel BW and, before that, head of controlling for Europe with the industrial company, Johnson Electrics, based in Hong Kong and Switzerland.

"PULSION forecasts a sale revenue growth of at least 20% and an EBIT margin of at least 15% for 2008. With the Management Board complete again, we look forward to the future with great optimism", stated Bradley Gould, Chairman of the Management Board of PULSION Medical Systems AG.

PULSION Medical Systems SE

PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals. The business unit PULSION Critical Care covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients. Products and activities of the business unit PULSION Pharma are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology. PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines. Further information about PULSION is available at www.pulsion.com.